Sana Biotechnology to Present at March 2026 Investor Conferences
Rhea-AI Summary
Sana Biotechnology (NASDAQ: SANA) will present live at two investor conferences in March 2026, with webcasts and 30-day replays available.
Sana will present a business overview and update at the Cowen 46th Annual Health Care Conference on March 2, 2026 at 1:10 p.m. ET and at the Citizens Life Sciences Conference on March 11, 2026 at 1:40 p.m. ET. Webcasts are on the company Investor Relations page and replays remain for 30 days.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
SANA is down 3.14% while peers show mixed moves (e.g., IOVA up 1.77%, QURE down 1.8%, URGN down 2%), pointing to a stock-specific move rather than a broad biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | CFO appointment | Neutral | +0.0% | New EVP/CFO with long biopharma finance experience joining leadership team. |
| Jan 07 | Investor conference | Neutral | -4.4% | J.P. Morgan Healthcare Conference presentation with corporate overview webcast. |
| Dec 08 | Preclinical data | Positive | -9.8% | Nature Biotechnology publication of in vivo HSC gene editing using fusogen VLP platform. |
| Nov 24 | Investor conferences | Neutral | -0.8% | December 2025 Citi and Evercore conference presentations with business updates. |
| Nov 06 | Earnings and strategy | Positive | +1.0% | Q3 2025 results, pipeline focus on SC451 and SG293, and extended cash runway. |
Conference and presentation announcements have often seen flat-to-negative next-day moves, while a major positive scientific publication previously coincided with a notable decline.
Over the past several months, Sana has combined scientific progress with active investor outreach. A Nov 6, 2025 Q3 update highlighted focus on SC451 and SG293, improved expenses, and a cash runway into late 2026. Subsequent Nature Biotechnology data on its fusogen platform (Dec 8, 2025) and multiple investor conference slots in Dec 2025 and Jan 2026 framed the story. Today’s March 2026 conference appearances continue this pattern of regular business overviews to investors.
Market Pulse Summary
This announcement adds two March 2026 investor conferences, extending a pattern of regular webcasts and business updates. With shares at $4.01, above a 200-day MA of $3.77 yet still 38.78% below the 52-week high, the setup reflects both recovery from prior lows and residual caution. Investors may focus less on the schedule and more on what incremental detail emerges on SC451, SG293, cash runway, and any changes to strategic priorities during these presentations.
AI-generated analysis. Not financial advice.
SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in March. The presentations will feature a business overview and update.
- Sana will present at the Cowen 46th Annual Health Care Conference at 1:10 p.m. ET on Monday, March 2, 2026.
- Sana will present at the Citizens Life Sciences Conference at 1:40 p.m. ET on Wednesday, March 11, 2026.
The webcasts will be accessible on the Investor Relations page of Sana’s website at https://sana.com/. A replay of each presentation will be available at the same location for 30 days following the conference.
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA. For more information about Sana Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision; the Company’s participation at the Cowen 46th Annual Health Care Conference and the Citizens Life Sciences Conference; and the subject matter of the Company’s presentations at these conferences. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as economic, market and social disruptions. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Quarterly Report on Form 10-Q dated November 6, 2025. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com
FAQ
When will Sana Biotechnology (SANA) present at the Cowen Health Care Conference in March 2026?
What time and date is the Sana (SANA) presentation at the Citizens Life Sciences Conference?
How can investors watch Sana Biotechnology (SANA) webcasts for the March 2026 conferences?
Will Sana (SANA) provide replays of its March 2026 investor presentations and for how long?
What will Sana Biotechnology (SANA) present during the March 2026 investor conference webcasts?
